FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.503,11 -1.844,83 (-3,16%)
Vaxart, Inc. (VXRT)
Dopo ore:
| Chiusura precedente | 0,7316 |
| Aperto | 0,7181 |
| Denaro | 0,6735 x 300 |
| Lettera | 0,7086 x 600 |
| Min-Max giorno | 0,6900 - 0,7429 |
| Intervallo di 52 settimane | 0,5300 - 1,5900 |
| Volume | |
| Media Volume | 1.663.233 |
| Capitalizzazione | 124,671M |
| Beta (5 anni mensile) | 0,72 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5700 |
| Prossima data utili | 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 09 nov 2012 |
| Stima target 1A | 5,00 |
GlobeNewswireVaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023. Presentation Information: Title: Transmission blocking strategies via oral tablet vaccination and mucosal immune inductionSpeaker: Dr. Sean TuckerDate:
- GlobeNewswire
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET. The webcast of the fireside chat will be available on the Company’s Investor Presentations & Events page. A replay will be available on the Company’s website following the event. Management will also participate in one-on-on
- GlobeNewswire
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection rate, a non-statistically significant reduction in norovirus acute gastroenteritis (AGE), and a substantial reduction in viral shedding Conference call today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced top-line data from the
